Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    nct03876314
Previous Study | Return to List | Next Study

The Effect of Physical Activity on Cognition Relative to APOE Genotype (PAAD-2)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03876314
Recruitment Status : Recruiting
First Posted : March 15, 2019
Last Update Posted : September 27, 2019
Sponsor:
Collaborators:
Wake Forest University Health Sciences
National Institute on Aging (NIA)
Information provided by (Responsible Party):
University of North Carolina, Greensboro

Brief Summary:
Physical activity and Alzheimer's disease (PAAD-2) is a randomized control trial that will assess the effects of exercise on middle-aged (40-65 years) cognitively normal adults who have a heightened risk of Alzheimer's disease (AD) due to family history (FH+). The investigators will also assess the extent to which this effect is moderated by apolipoprotein epsilon-4 (APOE4) carrier status, and will gather critical new experimental evidence on the use of physical activity to improve cognitive performance by persons at the greatest risk of Alzheimer's disease.

Condition or disease Intervention/treatment Phase
Healthy Behavioral: Physical Activity Condition Not Applicable

Detailed Description:
In this study, the investigators follow up on their past research exploring the effects of physical activity on cognitive performance and underlying mechanisms. In particular, the investigators are interested in the potentially different effects that might be realized as a function of a person's genetic risk for Alzheimer's disease. In this study, the investigators extend past work by proposing a randomized clinical trial to: (a) test the causal link between physical activity and cognitive performance in middle-aged adults (40-65 years) with a family history, and (b) determine if the effect is moderated by apolipoprotein epsilon-4 (APOE4) carrier status. The investigators will collect neuroimaging measures of cerebral structure, white matter integrity, and resting state connectivity; assess putative biological markers; and (using moderated mediation analyses) increase understanding of underlying mechanisms and of the extent to which effects are moderated by APOE4 carrier status. To test hypotheses, the investigators will randomly assign 240 cognitively normal, middle-aged adults (recruited in 4 cohorts of 60) to a 1-year physical activity program or a usual care control. Those in the physical activity program will exercise 3 times/week for one hour at a local Young Men's Christian Association (YMCA). Those in the usual care control condition will be asked to maintain their normal lifestyle for one year and then will be given a short-term YMCA membership (contingent upon completion of testing sessions). The investigators will assess cognitive performance at pre-, mid-, and post-test, and obtain MRI scans and blood samples at pre- and post-test. The investigators will examine the effects of physical activity on cognitive performance and on neurological and biological mechanisms and will explore the moderating role of APOE4.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 240 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Care Provider, Outcomes Assessor)
Masking Description: The outcomes assessor will be masked to intervention assignment and APOE4 carrier status. The interventionist will be masked to APOE4 carrier status.
Primary Purpose: Basic Science
Official Title: The Effect of Physical Activity on Cognition Relative to APOE Genotype (PAAD-2)
Actual Study Start Date : May 23, 2019
Estimated Primary Completion Date : March 2023
Estimated Study Completion Date : March 2023

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Physical Activity Condition (PAC)
Subjects will be asked to attend exercise sessions which will include both aerobic and strength training 3 times a week for 1 year.
Behavioral: Physical Activity Condition
Subjects will attend group exercise sessions 3x/week for 1 year. Each subject will be encouraged to walk at a moderate intensity (target heart rate (HR)= 40-59% HR reserve) dependent on resting HR and age. At every session, exercise specialists will record the amount of time spent in the aerobic and strength training portions of the program and HR (assessed by palpation for 20-seconds) and rate of perceived exertion (RPE) from each participant during the middle portion of aerobic activity and RPE during the middle portion of strength training. Data from exercise logs and exercise specialist records will be reviewed for evidence of progression, consistent attainment of moderate intensity, and with respect to the prescribed duration of the aerobic and strength training components.

No Intervention: Usual Care Control (UCC)
Participants in the usual care control will maintain their normal health practices for 1 year. Participants will receive a bi-weekly health newsletter and will be contacted bi-weekly to answer any questions and inquire about the participant's health. Participants self-reported physical activity will be assessed monthly. In this fashion, participants will be contacted by staff every week. Usual care control participants that complete all study related activities including pre-, mid-, and post-test will receive a short-term YMCA membership after post-test.



Primary Outcome Measures :
  1. Change in performance on the cognitive domain of executive function as measured with Stroop Interference [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Stroop Interference.

  2. Change in performance on the cognitive domain of executive function as measured with Trail Making Test Interference [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Trail Making Test interference.

  3. Change in performance on the cognitive domain of executive function as measured with Dimensional Change Card Sort [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Dimensional Change Card Sort

  4. Change in performance on the cognitive domain of executive function as measured with the Flanker test. [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on the Flanker test.

  5. Change in performance on the cognitive domain of executive function as measured with Matrix Reasoning. [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in executive function will be assessed by comparing post-, mid-, and pre-test performance on Matrix Reasoning.

  6. Change in performance on the cognitive domain of memory as measured with the Auditory Verbal Learning Test. [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Auditory Verbal Learning Test.

  7. Change in performance on the cognitive domain of memory as measured with the Rey-Osterrieth Complex Figure Test [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Rey-Osterrieth Complex Figure Test

  8. Change in performance on the cognitive domain of memory as measured with the Picture Sequence test [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Picture Sequence test.

  9. Change in performance on the cognitive domain of memory as measured with the Mnemonic Similarity Test [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in memory will be assessed by comparing post-, mid-, and pre-test performance on the Mnemonic Similarity Test

  10. Change in performance on the cognitive domain of attention as measured with the Paced Auditory Serial Addition Test [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in attention will be assessed by comparing post-, mid-, and pre-test performance on the Paced Auditory Serial Addition Test

  11. Change in performance on the cognitive domain of attention as measured with the Forward Digit Span test [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in attention will be assessed by comparing post-, mid-, and pre-test performance on the Forward Digit Span

  12. Change in performance on the cognitive domain of working memory as measured with List Sort Working Memory [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the List Sort Working Memory

  13. Change in performance on the cognitive domain of working memory as measured with Spatial Working Memory [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Spatial Working Memory

  14. Change in performance on the cognitive domain of working memory as measured with Backward Digit Span [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Backward Digit Span

  15. Change in performance on the cognitive domain of processing speed as measured with the Wechsler Adult Intelligence Scale (WAIS-IV) Digit Symbol Task [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Wechsler Adult Intelligence Scale (WAIS-IV) Digit Symbol Task

  16. Change in performance on the cognitive domain of processing speed as measured with the Stroop Color Test [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Stroop Color Test

  17. Change in performance on the cognitive domain of processing speed as measured with the Stroop Word Test [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Stroop Word Test

  18. Change in performance on the cognitive domain of processing speed as measured with the Trail Making Test A [ Time Frame: Pretest, 6 months, and 12 months ]
    Change in working memory will be assessed by comparing post-, mid-, and pre-test performance on the Trail Making Test A


Secondary Outcome Measures :
  1. Change in brain morphology (whole brain and hippocampal volumes) [ Time Frame: Pretest and 12 months ]
    MRI will be used to measure brain morphology including whole brain and hippocampal volumes and change will be assessed from pre-test to post-test.

  2. Change in brain activity (resting-state connectivity) [ Time Frame: Pretest and 12 months ]
    Functional MRI will be used to measure brain activity including resting-state connectivity and change will be assessed from pre-test to post-test.

  3. Change in blood biomarkers (BDNF, irisin, IGF-1, glucose, insulin, TNF-⍺, serum amyloid protein (SAP), albumin, ApoE and ⍺-2 macroglobulin) [ Time Frame: Pretest and 12 months ]
    Blood samples will be taken following a 12-hour fast. Assays will be conducted for brain-derived neurotrophic factor (BDNF), irisin, insulin-like growth factor (IGF)-1, glucose, insulin, tumor necrosis factor (TNF)-⍺, serum amyloid protein (SAP), albumin, apolipoprotein E (ApoE) and ⍺-2 macroglobulin. Change from pre-test to post-test will be assessed.

  4. Change in cardiorespiratory fitness [ Time Frame: Pretest, 6 months, and 12 months ]
    Fitness will be assessed using a submaximal graded aerobic exercise test performed on a treadmill. Oxygen uptake (VO2) will be measured during a ramped exercise protocol performed until volitional exhaustion or test termination due to symptom limitations. Change across time will be assessed.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   40 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Family History of Alzheimer's disease, cognitive impairment
  • Able to communicate in English
  • Not currently meeting recommendations for physical activity (the recommendations are to exercise 3 days/week for 30+ minutes per day for longer than 3 months)
  • Willing to be randomized to either study condition
  • Willing to complete all study activities for 1 year

Exclusion Criteria:

  • Meet the criteria for clinical cognitive impairment
  • Unable to perform physical activity due to known cardiovascular, metabolic, or renal disease and are symptomatic or due to orthopedic limitations
  • Self-report history of confounding neurologic, psychiatric, or active severe or functionally disabling neurologic or medical diseases, or any other conditions that might limit exercise or pose a danger to the patient
  • Current use of medications to treat symptoms of Alzheimer's disease, that adversely affect cognition, or that impact heart rate
  • Meet the criteria for depression using the short form of the Center for Epidemiological Studies Depression Scale
  • Traveling for an extended period (>1 month) during the course of the study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03876314


Contacts
Layout table for location contacts
Contact: Shonda Mobley, MPH (336) 334-4765 ypmobley@uncg.edu
Contact: Jennifer Etnier, PhD (336) 334-3037 jletnier@uncg.edu

Locations
Layout table for location information
United States, North Carolina
University of North Carolina-Greensboro Recruiting
Greensboro, North Carolina, United States, 27402
Contact: Shonda Mobley, MPH    336-334-4765    ypmobley@uncg.edu   
Contact: Jennifer Etnier, PhD    336-334-3037    jletnier@uncg.edu   
Sponsors and Collaborators
University of North Carolina, Greensboro
Wake Forest University Health Sciences
National Institute on Aging (NIA)
Investigators
Layout table for investigator information
Principal Investigator: Jennifer Etnier, PhD UNC Greensboro
  Study Documents (Full-Text)

Documents provided by University of North Carolina, Greensboro:
Additional Information:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University of North Carolina, Greensboro
ClinicalTrials.gov Identifier: NCT03876314    
Other Study ID Numbers: 18-0228
R01AG058919 ( U.S. NIH Grant/Contract )
First Posted: March 15, 2019    Key Record Dates
Last Update Posted: September 27, 2019
Last Verified: September 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

Data documentation and de-identified data will be deposited for sharing consistent with applicable laws and regulations. Data will be available in a de-identified anonymous state and in a .csv format. Data will be shared by exporting the data from RedCap into a .csv file archived under the study principal investigator's institutional profile with University of North Carolina Greensboro (UNCG) University Libraries institutional repository North Carolina Digital Online Collection of Knowledge and Scholarship (NC DOCKS).

The data will also be shared through the Global Alzheimer's Association Interactive Network (GAAIN), a federated data system designed to foster data sharing and the development of collaborations for researchers interested in Alzheimer's related data. Interested scientists can explore meta data from PAAD-2 and from other studies. By becoming a partner, a description of PAAD-2 and link to contact the principal investigator will be made available at www.gaain.org.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Analytic Code
Time Frame: Consistent with the recommendations from the Collaboration for Alzheimer's Prevention (CAP), pre-randomization data will be deposited within 12 months of enrollment completion. Consistent with the National Institutes of Health (NIH) guidelines, post-randomization data will be embargoed until publication of the main findings of the study (i.e. those findings relevant to the specific aims) or two years following study closure (whichever comes earlier). Requests for data sharing that come before the end of the embargo period will be considered on a case-by-case basis by the principal investigator.
Access Criteria: Investigators interested in having access to the data will submit their request through GAAIN and then will be asked to submit a proposal to the principal investigator. The proposal should include institutional affiliation, a current resume or vita, source of funding (if applicable), and a detailed explanation of the research question and the data required. All applicants will also be required to sign an agreement of confidentiality. This agreement prohibits the use of the data in any way that would allow for the identification of individual participants.

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No